Biotech Startup Licenses Technology From UCSD, Raises $18M

A new, biotech startup focused on delivery of nucleic acid therapeutics, Solstice Biologics, said last week that it has licensed technology developed at UC San Diego, and received $18M in a Series A funding. Solstice, which is based in San Francisco, said the technology was licensed from the University of California, San Diego, and is based on research from Professor Steven Dowdy , Ph.D., and his colleagues at UC San Diego School of Medicine. The funding round was led by venBio, and also included Aeris Capital. More information »